Skip to main content
. 2019 Apr 4;33(6):1073–1082. doi: 10.1097/QAD.0000000000002166

Fig. 2.

Proportion of nucleoside reverse transcriptase inhibitor drug-resistant mutations among study participants on antiretroviral therapy.

Fig. 2

The following amino acids substitutions were analyzed, as NRTI DRMs: E40F; M41L; E44D/A; A62V; K65R/E/N; D67N/G/E; T69D; K70R/E/G/Q/N/T; L74V/I; V75I; F77L; Y115F; F116Y; V118I; Q151M; M184I/V; L210W; T215Y/F/S/C/D/E/I/V/A/L/N; K219Q/E. (a) All participants on ART. (b) Participants on ART who are virologically suppressed (HIV-1 RNA ≤400 copies/ml). (c) Participants on ART who are virologically unsuppressed (HIV-1 RNA >400 copies/ml). ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitors; SDRM, surveillance drug resistant mutations.